Sponsor Dossier
Alphapharm
Sponsor Dossier for Alphapharm. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABACAVIR/LAMIVUDINE
- Brand: ABYRAZ
- Brand: ACAMPROSATE
- Brand: ACETEC
- Brand: ACICLOVIR
- Brand: ADENOSINE VIATRIS
- Brand: ADENOVIEW
- Brand: ADESAN
- Device (sponsor): Hypodermic needle, single-use, sterile
About
Alphapharm is an Australian Private Company with ABN 93 002 359 739, registered in NSW and currently active. The company has traded under the business names Mylan Australia and Viatris.
Portfolio
Alphapharm has 282 brands on the ARTG, with 190 indexable brands and 184 brands with Product Information on file. The portfolio includes 48 brands with at least one PBS-listed item and 16 brands with PBAC outcomes on record. No brands currently hold AusPARs.
Therapeutic focus —
Neurology: 63 brands — Cardiology: 57 brands — Infectious Disease: 50 brands — Endocrinology: 18 brands — Psychiatry: 16 brands — Oncology: 16 brands — Immunology: 10 brands — Ophthalmology: 9 brands — Urology: 7 brands — Haematology: 6 brands — Pain & Anaesthesia: 6 brands — Gastroenterology: 6 brands — Pain Management: 4 brands — Respiratory: 4 brands — Other: 3 brands — Dermatology: 2 brands — Uncategorised: 1 brand — Musculoskeletal: 1 brand — Complementary Medicine: 1 brand — Reproductive Health: 1 brand — Rare Disease: 1 brand
PBS footprint
Alphapharm has 48 brands with at least one PBS-listed item, with the portfolio last touching the PBS schedule on 1 May 2026.
Regulatory activity
The company's latest PBAC outcome was recorded on 1 May 2025, with 16 brands holding PBAC outcomes on record.